Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone + metformin versus chiglitazar + metformin in newly diagnosed type 2 diabetes mellitus with fatty liver disease
ChiCTR2500100193Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Chengdu Medical College
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pioglitazone, chiglitazar and metformin in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoints: Glycated hemoglobin, Homeostasis model assessment of insulin resistance and 9 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
pioglitazonechiglitazarmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2500100193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100193.